A new treatise on knee osteoarthritis has been published.
curcuRouge® has succeeded in proofing a potential for treating human knee osteoarthritis, particularly at an early stage.
top of page
セラバイオファーマの研究・開発・イベントにまつわる
最新ニュースを随時更新。
- Jun 12, 2023
Therabiopharma on stage at Kento Innovation Park Talk Session
Our CEO, Mr. Hashimoto, and Professor Kakeya from the Graduate School of Pharmaceutical Sciences at Kyoto University, who is also our...
- Sep 3, 2021
A new treatise has been published.(Updated)
Title Newly Developed Highly Bioavailable Curcumin Formulation, curcuRouge™, Reduces Neutrophil/Lymphocyte Ratio in the Elderly: A...
- Jul 27, 2021
Kyoto University Life Science Showcase 2020, San Diego
Therabiopharma is part of the Kyoto University Life Science Showcase 2020, San Diego This event will introduce biotech startups with...
- Jul 26, 2021
Therabiopharma exhibited at Supply Side West 2019
Therabiopharma CEO held a presentation at NCN (Nutrition Capital Network) showcasing the latest innovations on nutraceuticals and...
- Jul 26, 2021
Press Release: CMG and Oxaliplatin studies for colon cancer
Therabiopharma (Japan Based Bio-Venture) Reports 10,000 Times Higher Curcumin Concentration in Bloodstream Clearly Demonstrates Strong...
bottom of page